Latest Content

Adial seeks FDA priority voucher to speed AD04 review, a biomarker-guided therapy aiming to curb heavy drinking in alcohol use disorder.

FDA expands Caplyta label to prevent schizophrenia relapse, cutting risk 63% and showing weight-neutral tolerability for sustained long-term stability.

FDA accelerates psychedelic drug development to advance agents for TRD, PTSD, and AUD.

Explore GLP-1 agonists and their "truly transformative" role in psychiatry in this podcast.

In this CME article, learn how depression hides in organ failure, transplants, neurologic disease, and hormonal shifts—plus screening tips and safer treatment choices.

AXS-05 for Alzheimer disease agitation nears FDA decision date.

How do estrogen, testosterone, and aromatase shape binge eating and bulimia risk? Let's explore brain biomarkers and future hormone-aware treatments.

Psychiatry experts explain why off-label psych meds and polypharmacy can be essential.

AFSP and JED plan a 2026 merger to form the largest US suicide prevention nonprofit, uniting research, youth mental health programs, advocacy, and community support.

Psychedelic therapies surge, but a rushed FDA shortcut risks safety; learn why ibogaine claims need rigorous trials and oversight.

Two-dose oral R‑MDMA, EMP-01, cuts social anxiety symptoms and real‑world avoidance in phase 2a study, with strong responder rates and good tolerability.

Evidence links some hormonal contraceptives—especially in teens—to higher depression risk; see which types matter and how to monitor mood.